Unit –I: General Aspects of Pharmacological Screening
1. Introduction to Pharmacological Screening Methods 1 − 6
2. Study of CPCSEA and OECD Guidelines 7 − 11
3. Experimental Common Lab Animals:
(a) Different Species and Strains of Animals 12 − 20
(b) Popular Transgenic and Mutant Animals (Dr. Nishant S. Jain) 21 − 32
4. Routes of Drug Administration in Laboratory Animals 33 45
5. Various Techniques of Blood Collection and Euthanasia 46 − 55
6. Dose Selection, Calculation, Conversions and Preparation of Drug Solutions, Suspension Control. (Dr. Nishant S. Jain) 56 − 60
7. Rationale for Selection of Animal Species and Sex for the study 61 − 64
Unit-II: Preclinical Screening Models for CNS
8. Nootropics/Anti-alzheimers 65 − 86
9. Antiparkinsons 87 − 99
10. Antiinflammatory 100 − 114
11. Analgesics 115 − 128
12. Antipyretics 129 − 131
13. General Anaesthetics 132 − 139
14. Sedative and Hypnotics 140 − 154
15. Antipsychotics 155 − 171
16. Antidepressants 172 − 185
17. Antiepileptics 186 − 194
18. Antianxiety 195 − 208
Unit-III: Preclinical Screening Models for ANS
19. Sympathomimetics 209 − 214
20. Sympatholytics 215 − 219
21. Parasympathomimetics 220 − 224
22. Parasympatholytics 225 − 229
23. Skeletal Muscle Relaxants 230 − 234
24. Drugs Acting on Eyes 235 − 243
25. Local Anaesthetics 244 − 251
Unit –IV: Preclinical Screening Models for CVS
26. Antihypertensive 252 − 263
27. Antiarrhythmic 264 − 273
28. Antianginal 274 − 279
29. Antidyslipidemic 280 − 285
Unit-V: Preclinical Screening Models for Respiratory System
30. Antiasthmatics 286 − 302
31. Antitussive 303 − 311
Unit-VI: Preclinical Screening Models for Urinary System
32. Diuretics 312 − 317
Unit-VII: Preclinical Screening Models for Drugs Acting on Blood
33. Antiaggregatory, Coagulants and Anticoagulants 318 − 340
Unit-VIII: Preclinical Screening Models for Diabetes
34. Type I Diabetes 341 − 347
35. Type II Diabetes 348 − 364
Unit-IX: Preclinical Screening Models for GIT
36. Antiulcer 365 − 370
37. Antimotility 371 − 376
38. Antiemetics 377 − 385
Unit-X: Preclinical Screening Models for Cancer
39. Anticancer and Immunosuppressants 386 − 392
Unit-XI: Research Methodology and Biostatistics
40. Selection of Research Topic, Review of Literature, Research Hypothesis and Study Design 393 − 407
41. Pre-clinical Data Analysis and Interpretation using Students ‘t’ test and One-way ANOVA 408 − 415
42. Graphical Representation of Data 416 − 423
Index 424 − 432
Reviews
There are no reviews yet.